Skip to main content

Table 3 Pathological and immunohistochemical characteristics in patients with G-NENs (n = 135)

From: Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience

Variables NET G1 (n = 39, %) NET G2 (n = 7, %) NEC G3 (n = 69, %) MANEC (n = 20, %) P value
Depth of invasion      <0.001
 T1 29 (74.4) 3 (42.9) 4 (5.8) 1 (5.0)  
 T2 7 (17.9) 0 (0.0) 6 (8.7) 3 (15.0)  
 T3 2 (5.1) 0 (0.0) 23 (33.3) 9 (45.0)  
 T4 1 (2.6) 4 (57.1) 36 (52.2) 7 (35.0)  
Lymph node metastasis      <0.001
 N0 36 (92.3) 3 (42.9) 4 (5.8) 3 (15.0)  
 N1 3 (7.7) 4 (57.1) 65 (94.2) 17 (85.0)  
Distant metastasis      0.001
 M0 39 (100.0) 5 (71.4) 60 (87.0) 14 (70.0)  
 M1 0 (0.0) 2 (28.6) 9 (13.0) 6 (30.0)  
TNM stage      <0.001
 I/II 36 (92.3) 3 (42.9) 4 (5.8) 2 (10.0)  
 III/IV 3 (7.7) 4 (57.1) 65 (94.2) 18 (90.0)  
Vascular invasion 0 (0.0) 2 (28.6) 33 (47.8) 8 (40.0) <0.001
Immunohistochemical features
 CgA (+) 32 (82.1) 4 (57.1) 57 (82.6) 15 (75.0) 0.367
 Syn (+) 29 (74.4) 5 (71.4) 53 (76.8) 13 (65.0) 0.728
 NSE (+) 9 (23.1) 2 (28.6) 16 (23.2) 2 (10.0) 0.594
 CD56 (+) 16 (41.0) 4 (57.1) 38 (55.1) 5 (25.0) 0.086
  1. G-NENs gastric neuroendocrine neoplasms, NET G1 neuroendocrine tumor G1, NET G2 neuroendocrine tumor G2, NEC G3 neuroendocrine carcinoma G3, MANEC mixed adenoneuroendocrine carcinoma, TNM tumor-node-metastasis, CgA Chromogranin A, Syn synaptophysin, NSE neuron specific enolase